Hepatitis C virus infection: 10 years after the discovery of the virus

被引:22
|
作者
Ramadori, G [1 ]
Meier, V [1 ]
机构
[1] Univ Gottingen, Abt Gastroenterol & Endocrinol, D-37075 Gottingen, Germany
关键词
cirrhosis; hepatitis C virus; prevalence;
D O I
10.1097/00042737-200105000-00001
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The hepatitis C virus (HCV) causes an acute but very often chronic liver disease. An estimated 3% of the world population is chronically infected with HCV, Chronic hepatitis C is the major cause of cirrhosis and hepatocellular carcinoma (HCC), which most often lead to liver transplantation. HCV is a single-stranded enveloped RNA virus; it belongs to the flaviviridae family. The virus has been classified into six genotypes, some of which are distributed worldwide, others of which are confined to more restricted areas. The genotype is an independent predictor of response to antiviral treatment. Blood transfusion was a major risk factor for acquiring HCV infection before donor screening for surrogate marker testing for non-A, non-B (NANB) hepatitis began in the mid-1980s, followed by screening for antibody to HCV in 1990. Today, intravenous drug use and high-risk sexual activity are the most frequently identified risk factors associated with HCV infection. The prevalence of people with unknown HCV infection worldwide is high, so it is necessary to screen people with risk factors. The treatment of patients with chronic HCV infection who have not been treated previously should consist of interferon alpha (IFN-alpha) and ribavirin. Eur J Gastroenterol Hepatol 13:465-471 (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:465 / 471
页数:7
相关论文
共 50 条
  • [31] Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection
    Angel Martinez, Miguel
    Franco, Sandra
    ANTIVIRAL DRUG DISCOVERY AND DEVELOPMENT, 2021, 1322 : 139 - 157
  • [32] Current drug discovery strategies for treatment of hepatitis C virus infection
    Cheng, K. -C.
    Gupta, Samir
    Wang, Hongwu
    Uss, Annette S.
    Njoroge, George F.
    Hughes, Eric
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2011, 63 (07) : 883 - 892
  • [33] ACUTELY RELAPSING HEPATITIS A VIRUS INFECTION AFTER FIVE YEARS OF INITIAL INFECTION
    Ibrahim, M.
    Ibrahim, A.
    Krolikowski, M.
    Haddad, I.
    Sheikh, O.
    Bhattad, P.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2020, 68 (02) : 533 - 534
  • [34] Concurrent hepatitis B and C virus infection: Is hepatitis C virus stronger?
    Liaw, YF
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (06) : 597 - 598
  • [35] Hepatitis C Virus Replication in Patients with Occult Hepatitis C Virus Infection
    Carreno, Vicente
    Bartolome, Javier
    Castillo, Inmaculada
    Antonio Quiroga, Juan
    HEPATOLOGY, 2009, 49 (06) : 2128 - 2129
  • [36] Hepatitis C virus infection: virus/host interactions
    Pawlotsky, JM
    JOURNAL OF VIRAL HEPATITIS, 1998, 5 : 3 - 8
  • [37] Hepatitis C Virus as a Possible Helper Virus in Human Hepatitis Delta Virus Infection
    Crobu, Maria Grazia
    Ravanini, Paolo
    Impaloni, Clotilde
    Martello, Claudia
    Bargiacchi, Olivia
    Di Domenico, Christian
    Faolotto, Giulia
    Macaluso, Paola
    Mercandino, Alessio
    Riggi, Miriam
    Quaglia, Vittorio
    Andreoni, Stefano
    Pirisi, Mario
    Smirne, Carlo
    VIRUSES-BASEL, 2024, 16 (06):
  • [38] Hepatitis C Virus and Hepatitis B Virus Co-Infection
    Shih, Yi-Fen
    Liu, Chun-Jen
    VIRUSES-BASEL, 2020, 12 (07):
  • [39] Hepatitis B virus and hepatitis C virus infection in immunocompromised patients
    Hwang, Jessica P.
    Torres, Harrys A.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2018, 31 (06) : 535 - 541
  • [40] Co-infection with hepatitis B virus and hepatitis C virus
    Mitre, Heloisa Pedrosa
    de Mendonca, Joao Silva
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2007, 11 : 33 - 35